The effect of dermatan sulfate on in vitro human plasma coagulation, platelet aggregation and βTG/PF4 release

E. Cofrancesco, M. Colombi, F. Gianese, M. Cortellaro

Research output: Contribution to journalArticlepeer-review

Abstract

We evaluated the in vitro anticoagulant action of dermatan sulfate (DS) (aPTT, antiXa, anti-thrombin) and its effect on human platelet aggregation and βTG/PF4 release induced by threshold doses of aggregating agents, compared with standard heparin (SH). In pooled plasma, DS prolonged aPTT much less than SH, had no measurable antiXa activity, showed an anti-thrombin activity similar to that shown by SH at a tenfold higher dilution. DS had no direct effect on human platelet aggregation and βTG/PF4 release. More-over it did not significantly affect platelet aggregation and release by ADP and collagen, whereas it completely inhibited platelet aggregation and βTG/PF4 release by thrombin. These data in vitro confirm that thrombin inhibition induced by DS is accompained by a far lesser aPTT prolongation compared to heparin, without any appreciable interference with platelet function.

Original languageEnglish
Pages (from-to)405-414
Number of pages10
JournalThrombosis Research
Volume57
Issue number3
DOIs
Publication statusPublished - Feb 1 1990

Keywords

  • anticoagulant activity
  • Dermatan sulfate
  • platelet aggregation
  • βTG/PF4 release

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Fingerprint

Dive into the research topics of 'The effect of dermatan sulfate on in vitro human plasma coagulation, platelet aggregation and βTG/PF4 release'. Together they form a unique fingerprint.

Cite this